From: Comprehensive analysis of human microRNA target networks
MicroRNA | Number of Targets | Molecules in KeyMolnet Networks | Top Pathway | Score | p-Value | Top Disease | Score | p-Value | Top Pathological Event | Score | p-Value |
---|---|---|---|---|---|---|---|---|---|---|---|
hsa-let-7a | 244 | 1022 | Transcriptional regulation by p53 | 593 | 2.69E-179 | Viral myocarditis | 113 | 1.21E-34 | Cancer | 206 | 1.31E-62 |
hsa-let-7b | 242 | 1016 | Transcriptional regulation by p53 | 594 | 1.83E-179 | Viral myocarditis | 113 | 9.32E-35 | Cancer | 206 | 7.66E-63 |
hsa-let-7c | 243 | 1020 | Transcriptional regulation by p53 | 593 | 2.49E-179 | Viral myocarditis | 113 | 1.11E-34 | Cancer | 206 | 1.10E-62 |
hsa-let-7d | 145 | 885 | Transcriptional regulation by RB/E2F | 836 | 2.18E-252 | Chronic myelogenous leukemia | 72 | 1.95E-22 | Cancer | 130 | 9.68E-40 |
hsa-let-7e | 236 | 1111 | Transcriptional regulation by p53 | 575 | 8.90E-174 | Viral myocarditis | 116 | 1.20E-35 | Cancer | 175 | 1.86E-53 |
hsa-let-7f | 244 | 1022 | Transcriptional regulation by p53 | 593 | 2.69E-179 | Viral myocarditis | 113 | 1.21E-34 | Cancer | 206 | 1.31E-62 |
hsa-let-7g | 245 | 1022 | Transcriptional regulation by p53 | 593 | 2.69E-179 | Viral myocarditis | 113 | 1.21E-34 | Cancer | 206 | 1.31E-62 |
hsa-let-7i | 245 | 1022 | Transcriptional regulation by p53 | 593 | 2.69E-179 | Viral myocarditis | 113 | 1.21E-34 | Cancer | 206 | 1.31E-62 |
hsa-miR-9 | 352 | 1115 | Transcriptional regulation by PPARa | 340 | 5.28E-103 | Hepatocellular carcinoma | 72 | 1.69E-22 | Cancer | 171 | 3.50E-52 |
hsa-miR-17 | 195 | 961 | Transcriptional regulation by RB/E2F | 971 | 3.27E-293 | Chronic myelogenous leukemia | 92 | 2.83E-28 | Cancer | 181 | 3.58E-55 |
hsa-miR-19a | 226 | 1094 | Transcriptional regulation by RB/E2F | 760 | 2.10E-229 | Chronic myelogenous leukemia | 113 | 1.26E-34 | Cancer | 253 | 7.04E-77 |
hsa-miR-19b | 225 | 1094 | Transcriptional regulation by RB/E2F | 760 | 2.10E-229 | Chronic myelogenous leukemia | 113 | 1.26E-34 | Cancer | 253 | 7.04E-77 |
hsa-miR-20a | 165 | 1038 | Transcriptional regulation by RB/E2F | 856 | 1.64E-258 | Chronic myelogenous leukemia | 87 | 6.09E-27 | Cancer | 85 | 3.33E-26 |
hsa-miR-20b | 198 | 981 | Transcriptional regulation by RB/E2F | 962 | 2.35E-290 | Chronic myelogenous leukemia | 98 | 3.39E-30 | Cancer | 183 | 6.98E-56 |
hsa-miR-26a | 148 | 672 | Transcriptional regulation by RB/E2F | 919 | 1.76E-277 | Chronic myelogenous leukemia | 107 | 6.15E-33 | Cancer | 181 | 3.20E-55 |
hsa-miR-26b | 148 | 672 | Transcriptional regulation by RB/E2F | 919 | 1.76E-277 | Chronic myelogenous leukemia | 107 | 6.15E-33 | Cancer | 181 | 3.20E-55 |
hsa-miR-27a | 229 | 1192 | Transcriptional regulation by CREB | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 95 | 1.96E-29 | Cancer | 194 | 3.05E-59 |
hsa-miR-27b | 261 | 1337 | Transcriptional regulation by CREB | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 4.51E-29 | Cancer | 211 | 4.11E-64 |
hsa-miR-29a | 119 | 543 | Transcriptional regulation by Ets-domain family | 430 | 4.36E-130 | Glioma | 85 | 3.46E-26 | Cancer | 139 | 1.41E-42 |
hsa-miR-29b | 118 | 578 | Transcriptional regulation by Ets-domain family | 422 | 1.15E-127 | Glioma | 82 | 1.55E-25 | Cancer | 146 | 1.44E-44 |
hsa-miR-29c | 118 | 543 | Transcriptional regulation by Ets-domain family | 430 | 4.36E-130 | Glioma | 85 | 3.46E-26 | Cancer | 139 | 1.41E-42 |
hsa-miR-30a | 455 | 1494 | Transcriptional regulation by RB/E2F | 777 | 9.43E-235 | Chronic myelogenous leukemia | 86 | 1.11E-26 | Cancer | 195 | 2.39E-59 |
hsa-miR-30b | 455 | 1480 | Transcriptional regulation by RB/E2F | 781 | 1.08E-235 | Chronic myelogenous leukemia | 87 | 7.01E-27 | Cancer | 188 | 1.92E-57 |
hsa-miR-30c | 454 | 1495 | Transcriptional regulation by RB/E2F | 778 | 6.13E-235 | Chronic myelogenous leukemia | 86 | 1.15E-26 | Cancer | 191 | 3.63E-58 |
hsa-miR-30d | 452 | 1491 | Transcriptional regulation by RB/E2F | 778 | 7.28E-235 | Chronic myelogenous leukemia | 86 | 1.01E-26 | Cancer | 195 | 1.96E-59 |
hsa-miR-30e | 455 | 1481 | Transcriptional regulation by RB/E2F | 780 | 1.29E-235 | Chronic myelogenous leukemia | 87 | 7.25E-27 | Cancer | 188 | 2.05E-57 |
hsa-miR-32 | 261 | 905 | Transcriptional regulation by RB/E2F | 842 | 2.74E-254 | Gastric cancer | 80 | 8.85E-25 | Cancer | 157 | 4.19E-48 |
hsa-miR-92a | 219 | 642 | Transcriptional regulation by MEF2 | 335 | 1.51E-101 | Viral myocarditis | 59 | 1.62E-18 | Epithelial-mesenchymal transition | 83 | 7.76E-26 |
hsa-miR-92b | 258 | 701 | Transcriptional regulation by MEF2 | 328 | 1.59E-99 | Viral myocarditis | 60 | 1.23E-18 | Cancer | 94 | 3.97E-29 |
hsa-miR-93 | 195 | 958 | Transcriptional regulation by RB/E2F | 972 | 2.37E-293 | Chronic myelogenous leukemia | 92 | 2.47E-28 | Cancer | 181 | 2.77E-55 |
hsa-miR-96 | 142 | 688 | Transcriptional regulation by Ets-domain family | 407 | 3.42E-123 | Viral myocarditis | 36 | 1.06E-11 | Cancer | 106 | 1.37E-32 |
hsa-miR-98 | 162 | 671 | Transcriptional regulation by Myb | 549 | 4.73E-166 | Viral myocarditis | 85 | 2.66E-26 | Cancer | 126 | 1.42E-38 |
hsa-miR-101 | 188 | 806 | Transcriptional regulation by AP-1 | 492 | 1.10E-148 | Hepatocellular carcinoma | 70 | 6.40E-22 | Cancer | 127 | 4.26E-39 |
hsa-miR-106b | 164 | 1028 | Transcriptional regulation by RB/E2F | 854 | 7.21E-258 | Chronic myelogenous leukemia | 87 | 5.48E-27 | Cancer | 85 | 2.93E-26 |
hsa-miR-124 | 285 | 1346 | Transcriptional regulation by RB/E2F | 756 | 3.57E-228 | Chronic myelogenous leukemia | 83 | 9.34E-26 | Cancer | 185 | 1.90E-56 |
hsa-miR-137 | 288 | 941 | Transcriptional regulation by MITF family | 339 | 1.19E-102 | Adult T cell lymphoma/leukemia | 66 | 1.30E-20 | Cancer | 179 | 1.00E-54 |
hsa-miR-147 | 199 | 867 | Transcriptional regulation by RB/E2F | 805 | 4.06E-243 | Chronic myelogenous leukemia | 113 | 6.60E-35 | Cancer | 132 | 2.57E-40 |
hsa-miR-153 | 154 | 1019 | Transcriptional regulation by Myb | 507 | 2.35E-153 | Multiple myeloma | 60 | 6.44E-19 | Cancer | 174 | 4.31E-53 |
hsa-miR-218 | 155 | 830 | Transcriptional regulation by AP-1 | 344 | 2.28E-104 | Hepatocellular carcinoma | 69 | 1.63E-21 | Cancer | 136 | 1.52E-41 |
hsa-miR-372 | 101 | 562 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 85 | 1.90E-26 | Cancer | 144 | 2.75E-44 |
hsa-miR-429 | 123 | 634 | Transcriptional regulation by RB/E2F | 918 | 2.45E-277 | Chronic myelogenous leukemia | 76 | 1.71E-23 | Cancer | 130 | 5.28E-40 |
hsa-miR-495 | 156 | 601 | Transcriptional regulation by Ets-domain family | 431 | 2.14E-130 | Rheumatoid arthritis | 77 | 5.90E-24 | Adipogenesis | 79 | 1.32E-24 |
hsa-miR-506 | 394 | 1536 | Transcriptional regulation by Ets-domain family | 317 | 4.69E-96 | Viral myocarditis | 99 | 1.73E-30 | Cancer | 172 | 1.43E-52 |
hsa-miR-519a | 281 | 1256 | Transcriptional regulation by RB/E2F | 811 | 5.32E-245 | Chronic myelogenous leukemia | 106 | 1.34E-32 | Cancer | 220 | 8.03E-67 |
hsa-miR-519b-3p | 281 | 1256 | Transcriptional regulation by RB/E2F | 811 | 5.32E-245 | Chronic myelogenous leukemia | 106 | 1.34E-32 | Cancer | 220 | 8.03E-67 |
hsa-miR-519c-3p | 281 | 1256 | Transcriptional regulation by RB/E2F | 811 | 5.32E-245 | Chronic myelogenous leukemia | 106 | 1.34E-32 | Cancer | 220 | 8.03E-67 |
hsa-miR-520a-3p | 184 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 6.95E-29 | Cancer | 146 | 1.12E-44 |
hsa-miR-520b | 182 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 6.95E-29 | Cancer | 146 | 1.12E-44 |
hsa-miR-520c-3p | 182 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 93 | 9.28E-29 | Cancer | 145 | 1.77E-44 |
hsa-miR-520d-3p | 183 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 6.95E-29 | Cancer | 146 | 1.12E-44 |
hsa-miR-520e | 184 | 690 | Transcriptional regulation by RB/E2F | 1022 | 2.23E-308 | Chronic myelogenous leukemia | 94 | 6.95E-29 | Cancer | 146 | 1.12E-44 |
hsa-miR-603 | 252 | 1150 | Transcriptional regulation by Ets-domain family | 344 | 3.26E-104 | Multiple myeloma | 84 | 4.36E-26 | Cancer | 161 | 4.24E-49 |